<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Neurofibromatosis Type 1 - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "↳ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Neurofibromatosis Type 1</span>
        </nav>

        <header class="page-header">
            <h1>Neurofibromatosis Type 1</h1>
            <div class="header-meta">
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0018975" target="_blank">
                        MONDO:0018975
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">hereditary cancer-predisposing syndrome</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Neurofibromatosis type 1 (NF1) is an autosomal dominant tumor predisposition syndrome caused by germline pathogenic variants in the NF1 tumor suppressor gene encoding neurofibromin. It is characterized by cafe-au-lait macules, neurofibromas, Lisch nodules, skeletal abnormalities, and increased risk of malignancy including optic pathway gliomas and malignant peripheral nerve sheath tumors (MPNST). NF1 exemplifies the RASopathy spectrum, with neurofibromin functioning as a RAS-GAP that normally negatively regulates RAS-MAPK signaling.
            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">NF1 Tumor Suppressor Loss</div>
                
                <div class="item-desc">Germline heterozygous NF1 mutations result in haploinsufficiency for neurofibromin function. Somatic loss or mutation of the remaining wild-type allele (second hit) eliminates neurofibromin completely, resulting in loss of RAS negative regulation and driving tumorigenesis. This follows Knudson&#39;s two-hit hypothesis.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        regulation of Ras protein signal transduction
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0046578" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↓ DECREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">RAS-MAPK Pathway Hyperactivation</div>
                
                <div class="item-desc">Neurofibromin normally accelerates GTP hydrolysis on RAS proteins, promoting the inactive GDP-bound state. Loss of neurofibromin results in prolonged RAS-GTP accumulation and constitutive activation of the RAS-RAF-MEK-ERK cascade, driving cell proliferation and survival.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Ras protein signal transduction
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007265" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↑ INCREASED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        MAPK cascade
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0000165" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↑ INCREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Uncontrolled Neural Crest Cell Proliferation</div>
                
                <div class="item-desc">Neural crest-derived cells (Schwann cells, melanocytes) show particular dependence on RAS-MAPK signaling. Loss of neurofibromin drives uncontrolled proliferation of these cell types, resulting in neurofibromas (Schwann cell tumors) and hyperpigmented skin lesions (cafe-au-lait macules from melanocyte hyperproliferation).</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Schwann cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002573" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        cell population proliferation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0008283" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↑ INCREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Tumor Development</div>
                
                <div class="item-desc">Biallelic NF1 loss in Schwann cells drives neurofibroma formation. Most neurofibromas remain benign, but plexiform neurofibromas have 8-13% lifetime risk of transformation to malignant peripheral nerve sheath tumors (MPNST), which require additional genetic events (TP53, CDKN2A loss).</div>
                
                
                
                
                
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">⬡</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Tumor_Development[&#34;Tumor Development&#34;]
    RAS_MAPK_Pathway_Hyperactivation[&#34;RAS-MAPK Pathway Hyperactivation&#34;]
    NF1_Tumor_Suppressor_Loss[&#34;NF1 Tumor Suppressor Loss&#34;]
    Uncontrolled_Neural_Crest_Cell_Proliferation[&#34;Uncontrolled Neural Crest Cell Proliferation&#34;]

    NF1_Tumor_Suppressor_Loss --&gt; RAS_MAPK_Pathway_Hyperactivation
    RAS_MAPK_Pathway_Hyperactivation --&gt; Uncontrolled_Neural_Crest_Cell_Proliferation
    Uncontrolled_Neural_Crest_Cell_Proliferation --&gt; Tumor_Development

    style Tumor_Development fill:#dbeafe
    style RAS_MAPK_Pathway_Hyperactivation fill:#dbeafe
    style NF1_Tumor_Suppressor_Loss fill:#dbeafe
    style Uncontrolled_Neural_Crest_Cell_Proliferation fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">8</span>
            </div>
            
            
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Cafe-au-lait Macules
                    
                    <span class="phenotype-freq">OBLIGATE</span>
                    
                    
                    <span class="phenotype-category">Dermatologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0007565" target="_blank">
                            HP:0007565
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Cutaneous Neurofibromas
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neoplastic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001067" target="_blank">
                            HP:0001067
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Plexiform Neurofibromas
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neoplastic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0009732" target="_blank">
                            HP:0009732
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33395032" target="_blank">PMID:33395032</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Given the potential of MEK inhibition as an effective and overall well tolerated medical treatment, the use of targeted agents in the NF1 population is likely to increase considerably."</div>
                
                
                <div class="evidence-explanation">Review confirms plexiform neurofibromas are a significant clinical problem in NF1 amenable to MEK inhibitor therapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Lisch Nodules
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Ophthalmologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0009737" target="_blank">
                            HP:0009737
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Optic Pathway Glioma
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neoplastic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0009734" target="_blank">
                            HP:0009734
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Malignant Peripheral Nerve Sheath Tumor
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Neoplastic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0100697" target="_blank">
                            HP:0100697
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32234870" target="_blank">PMID:32234870</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Almost all individuals with neurofibromatosis type 1 (NF1) develop peripheral nerve sheath tumors (PNSTs), mainly benign neurofibromas, however about 10% of PNSTs will undergo transformation to malignant peripheral nerve sheath tumors (MPNSTs)."</div>
                
                
                <div class="evidence-explanation">Review confirms approximately 10% of peripheral nerve sheath tumors in NF1 undergo malignant transformation to MPNST.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Scoliosis
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Skeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002650" target="_blank">
                            HP:0002650
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Learning Difficulties
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001249" target="_blank">
                            HP:0001249
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Most NF1 patients have normal IQ but specific learning disabilities. HP term for learning disability is used as closest match.</div>
                
                
                
    
    
                
    
    
            </div>
            
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NF1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Germline Loss-of-Function Mutations)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal Dominant</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    MEK Inhibitors
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Selumetinib is FDA-approved for symptomatic, inoperable plexiform neurofibromas in children aged 2 years and older. As a MEK inhibitor, it targets the downstream effector of hyperactive RAS signaling. Shrinkage of plexiform neurofibromas observed in clinical trials.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33395032" target="_blank">PMID:33395032</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The phase 2 trial (SPRINT) of selumetinib in pNF resulted in at least 20% reduction in the size of pNF from baseline in 71% of patients and was associated with clinically meaningful improvements. On the basis of this trial, selumetinib (Koselugo) received FDA approval for children 2 years of age..."</div>
                
                
                <div class="evidence-explanation">SPRINT trial demonstrated selumetinib efficacy in plexiform neurofibromas leading to FDA approval for pediatric NF1 patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Surgical Management
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Surgery for symptomatic neurofibromas causing pain, functional impairment, or disfigurement. Complete resection of plexiform neurofibromas often impossible due to infiltrative nature. Surgery is primary treatment for operable MPNST.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Surveillance Protocol
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000126" target="_blank">
                            MAXO:0000126
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Annual clinical evaluation including skin, skeletal, neurologic, and ophthalmologic examination. Annual ophthalmologic evaluation in children (optic glioma screening). MRI for symptomatic lesions or suspected MPNST. Blood pressure monitoring for renovascular disease or pheochromocytoma.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Genetic Counseling
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000079" target="_blank">
                            MAXO:0000079
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Genetic counseling for affected individuals and at-risk family members. Children of affected parents have 50% risk. High rate of de novo mutations means negative family history does not exclude NF1. Variable expressivity makes predicting severity difficult.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    NF1 Genetic Testing
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Neurofibromatosis Type 1
description: &gt;-
  Neurofibromatosis type 1 (NF1) is an autosomal dominant tumor predisposition syndrome
  caused by germline pathogenic variants in the NF1 tumor suppressor gene encoding
  neurofibromin. It is characterized by cafe-au-lait macules, neurofibromas, Lisch
  nodules, skeletal abnormalities, and increased risk of malignancy including optic
  pathway gliomas and malignant peripheral nerve sheath tumors (MPNST). NF1 exemplifies
  the RASopathy spectrum, with neurofibromin functioning as a RAS-GAP that normally
  negatively regulates RAS-MAPK signaling.
categories:
- Hereditary Cancer Syndrome
- Cancer Predisposition Syndrome
- Neurocutaneous Syndrome
- RASopathy
parents:
- hereditary cancer-predisposing syndrome
pathophysiology:
- name: NF1 Tumor Suppressor Loss
  description: &gt;-
    Germline heterozygous NF1 mutations result in haploinsufficiency for neurofibromin
    function. Somatic loss or mutation of the remaining wild-type allele (second hit)
    eliminates neurofibromin completely, resulting in loss of RAS negative regulation
    and driving tumorigenesis. This follows Knudson&#39;s two-hit hypothesis.
  biological_processes:
  - preferred_term: regulation of Ras protein signal transduction
    modifier: DECREASED
    term:
      id: GO:0046578
      label: regulation of Ras protein signal transduction
  downstream:
  - target: RAS-MAPK Pathway Hyperactivation
    description: Loss of RAS-GAP activity results in constitutive RAS-GTP accumulation
- name: RAS-MAPK Pathway Hyperactivation
  description: &gt;-
    Neurofibromin normally accelerates GTP hydrolysis on RAS proteins, promoting
    the inactive GDP-bound state. Loss of neurofibromin results in prolonged RAS-GTP
    accumulation and constitutive activation of the RAS-RAF-MEK-ERK cascade, driving
    cell proliferation and survival.
  biological_processes:
  - preferred_term: Ras protein signal transduction
    modifier: INCREASED
    term:
      id: GO:0007265
      label: Ras protein signal transduction
  - preferred_term: MAPK cascade
    modifier: INCREASED
    term:
      id: GO:0000165
      label: MAPK cascade
  downstream:
  - target: Uncontrolled Neural Crest Cell Proliferation
    description: RAS-MAPK activation promotes proliferation of neural crest derivatives
- name: Uncontrolled Neural Crest Cell Proliferation
  description: &gt;-
    Neural crest-derived cells (Schwann cells, melanocytes) show particular
    dependence on RAS-MAPK signaling. Loss of neurofibromin drives uncontrolled
    proliferation of these cell types, resulting in neurofibromas (Schwann cell
    tumors) and hyperpigmented skin lesions (cafe-au-lait macules from melanocyte
    hyperproliferation).
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  downstream:
  - target: Tumor Development
    description: Proliferating neural crest derivatives form benign and malignant tumors
- name: Tumor Development
  description: &gt;-
    Biallelic NF1 loss in Schwann cells drives neurofibroma formation. Most
    neurofibromas remain benign, but plexiform neurofibromas have 8-13% lifetime
    risk of transformation to malignant peripheral nerve sheath tumors (MPNST),
    which require additional genetic events (TP53, CDKN2A loss).
phenotypes:
- category: Dermatologic
  name: Cafe-au-lait Macules
  frequency: OBLIGATE
  diagnostic: true
  description: &gt;-
    Flat, hyperpigmented skin lesions present in &gt;99% of NF1 patients. Six or more
    cafe-au-lait macules &gt;5mm (prepubertal) or &gt;15mm (postpubertal) meet one of
    the NIH diagnostic criteria. Usually present at birth or develop in first years
    of life.
  phenotype_term:
    preferred_term: Multiple cafe-au-lait spots
    term:
      id: HP:0007565
      label: Multiple cafe-au-lait spots
- category: Neoplastic
  name: Cutaneous Neurofibromas
  frequency: VERY_FREQUENT
  diagnostic: true
  description: &gt;-
    Benign peripheral nerve sheath tumors arising from Schwann cells. Typically
    appear around puberty and increase in number with age. May cause cosmetic
    concerns but rarely become malignant.
  phenotype_term:
    preferred_term: Neurofibroma
    term:
      id: HP:0001067
      label: Neurofibroma
- category: Neoplastic
  name: Plexiform Neurofibromas
  frequency: FREQUENT
  description: &gt;-
    Diffuse neurofibromas involving multiple nerve fascicles, often present at birth.
    Can cause significant morbidity through mass effect, disfigurement, and pain.
    Approximately 8-13% lifetime risk of malignant transformation to MPNST.
  phenotype_term:
    preferred_term: Plexiform neurofibroma
    term:
      id: HP:0009732
      label: Plexiform neurofibroma
  evidence:
  - reference: PMID:33395032
    supports: SUPPORT
    snippet: &gt;-
      Given the potential of MEK inhibition as an effective and overall well
      tolerated medical treatment, the use of targeted agents in the NF1
      population is likely to increase considerably.
    explanation: &gt;-
      Review confirms plexiform neurofibromas are a significant clinical problem
      in NF1 amenable to MEK inhibitor therapy.
- category: Ophthalmologic
  name: Lisch Nodules
  frequency: VERY_FREQUENT
  diagnostic: true
  description: &gt;-
    Melanocytic hamartomas of the iris, appearing as tan-brown dome-shaped elevations.
    Present in &gt;90% of adults with NF1. Best visualized by slit-lamp examination.
    Pathognomonic for NF1 and do not affect vision.
  phenotype_term:
    preferred_term: Lisch nodules
    term:
      id: HP:0009737
      label: Lisch nodules
- category: Neoplastic
  name: Optic Pathway Glioma
  frequency: FREQUENT
  description: &gt;-
    Low-grade gliomas of the optic nerve, chiasm, or tract occur in 15-20% of NF1
    patients. Usually pilocytic astrocytomas. Most are asymptomatic and nonprogressive,
    but can cause vision loss. Peak incidence in first 6 years of life.
  phenotype_term:
    preferred_term: Optic nerve glioma
    term:
      id: HP:0009734
      label: Optic nerve glioma
- category: Neoplastic
  name: Malignant Peripheral Nerve Sheath Tumor
  frequency: OCCASIONAL
  description: &gt;-
    Aggressive sarcoma arising from peripheral nerves, often from transformation of
    plexiform neurofibromas. Lifetime risk 8-13% in NF1. Leading cause of NF1-related
    mortality. Presents with rapid growth, pain, or new neurologic deficits.
  phenotype_term:
    preferred_term: Neurofibrosarcoma
    term:
      id: HP:0100697
      label: Neurofibrosarcoma
  evidence:
  - reference: PMID:32234870
    supports: SUPPORT
    snippet: &gt;-
      Almost all individuals with neurofibromatosis type 1 (NF1) develop peripheral
      nerve sheath tumors (PNSTs), mainly benign neurofibromas, however about 10%
      of PNSTs will undergo transformation to malignant peripheral nerve sheath
      tumors (MPNSTs).
    explanation: &gt;-
      Review confirms approximately 10% of peripheral nerve sheath tumors in NF1
      undergo malignant transformation to MPNST.
- category: Skeletal
  name: Scoliosis
  frequency: FREQUENT
  description: &gt;-
    Spinal curvature occurs in 10-30% of NF1 patients. Can be idiopathic-type or
    dystrophic (sharply angulated, short segment) forms. Dystrophic scoliosis may
    progress rapidly and require surgical intervention.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
- category: Neurologic
  name: Learning Difficulties
  frequency: FREQUENT
  description: &gt;-
    Learning disabilities and attention deficits occur in 50-75% of children with NF1.
    Intelligence is usually normal but specific learning disabilities, ADHD, and
    executive function problems are common. Motor coordination difficulties may occur.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  notes: &gt;-
    Most NF1 patients have normal IQ but specific learning disabilities. HP term
    for learning disability is used as closest match.
biochemical:
- name: NF1 Genetic Testing
  notes: &gt;-
    Comprehensive NF1 testing identifies germline pathogenic variants including
    point mutations, small insertions/deletions, large deletions/duplications,
    and deep intronic variants. Approximately 50% are de novo mutations. Mutation
    detection rate exceeds 95% with comprehensive testing including deletion/duplication
    analysis.
genetic:
- name: NF1
  association: Germline Loss-of-Function Mutations
  inheritance:
  - name: Autosomal Dominant
  notes: &gt;-
    NF1 (17q11.2) encodes neurofibromin, a large protein with RAS-GAP domain that
    negatively regulates RAS signaling. Germline mutations include truncating variants,
    missense mutations in the GAP domain, splice site variants, and large deletions
    (5% of cases, associated with more severe phenotype). De novo mutation rate is
    approximately 50%. Penetrance is essentially complete but expressivity is highly
    variable, even within families.
treatments:
- name: MEK Inhibitors
  description: &gt;-
    Selumetinib is FDA-approved for symptomatic, inoperable plexiform neurofibromas
    in children aged 2 years and older. As a MEK inhibitor, it targets the downstream
    effector of hyperactive RAS signaling. Shrinkage of plexiform neurofibromas
    observed in clinical trials.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:33395032
    supports: SUPPORT
    snippet: &gt;-
      The phase 2 trial (SPRINT) of selumetinib in pNF resulted in at least 20%
      reduction in the size of pNF from baseline in 71% of patients and was associated
      with clinically meaningful improvements. On the basis of this trial, selumetinib
      (Koselugo) received FDA approval for children 2 years of age and older with
      inoperable, symptomatic pNF.
    explanation: &gt;-
      SPRINT trial demonstrated selumetinib efficacy in plexiform neurofibromas
      leading to FDA approval for pediatric NF1 patients.
- name: Surgical Management
  description: &gt;-
    Surgery for symptomatic neurofibromas causing pain, functional impairment, or
    disfigurement. Complete resection of plexiform neurofibromas often impossible
    due to infiltrative nature. Surgery is primary treatment for operable MPNST.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Surveillance Protocol
  description: &gt;-
    Annual clinical evaluation including skin, skeletal, neurologic, and ophthalmologic
    examination. Annual ophthalmologic evaluation in children (optic glioma screening).
    MRI for symptomatic lesions or suspected MPNST. Blood pressure monitoring for
    renovascular disease or pheochromocytoma.
  treatment_term:
    preferred_term: cancer screening
    term:
      id: MAXO:0000126
      label: cancer screening
- name: Genetic Counseling
  description: &gt;-
    Genetic counseling for affected individuals and at-risk family members. Children
    of affected parents have 50% risk. High rate of de novo mutations means negative
    family history does not exclude NF1. Variable expressivity makes predicting
    severity difficult.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
disease_term:
  preferred_term: neurofibromatosis type 1
  term:
    id: MONDO:0018975
    label: neurofibromatosis type 1
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Neurofibromatosis_Type_1.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>